Oncologists are perturbed by the increase in early-onset tumors and the potential role of lifestyle, though this may not ...

Investorideas ( ), a go-to investing platform, releases the second of a two-part series looking at news and developments for the <a target=_blank ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

Cachexia is a wasting syndrome prevalent in cancer patients (as well as patients with other conditions) that is marked by weight loss, loss of muscle mass, fatigue, and lack of appetite, and is ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

Mid-stage data reported at the ESMO congress in Barcelona showed that ponsegromab was able to increase weight by 5.6% at the ...

Opens in a new tab or window Cabozantinib (Cabometyx) significantly improved progression-free survival (PFS) in patients with previously treated, progressive advanced extrapancreatic or pancreatic ...

The same set of clinical data on Cabometyx and Tecentriq in prostate cancer has led to two distinct regulatory plans between ...

The Alliance for Clinical Trials in Oncology today announced that final results will be presented at ESMO 2024 from CABINET ...

Exelixis releases positive phase 3 data on Cabometyx for pancreatic and extra-pancreatic neuroendocrine tumors, seeking ...